Acute Functional Gastric Outlet Obstruction Associated With Low-Dose Tirzepatide

Obesity has become a significant global challenge, highlighting the need for effective weight loss strategies. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a promising solution, with tirzepatide gaining significant popularity for its efficacy in promoting weight loss. This case report highlights a 57-year-old male patient with type 2 diabetes on a low dose of tirzepatide who initially presented with severe abdominal pain and vomiting, with symptoms resembling those of acute functional gastric outlet obstruction. Despite initial suspicion of an anatomical obstruction, no abnormalities were found on esophagogastroduodenoscopy. The symptoms resolved following the discontinuation of tirzepatide, suggesting a causative link. This case underscores the importance of physician awareness and patient education regarding potential severe gastrointestinal side effects associated with tirzepatide, even at low doses.